[1] Japan Ministry of Health, Labor and Welfare: The 2012 National Health and Nutrition Survey in Japan.
http://www.mhlw.go.jp/stf/houdou/0000032074.html
[2] Lakey, W.C., Barnard, K., Batch, B.C., Chiwell, K., Tasneem, A. and Green, J.B. (2013) Are Current Clinical Trials in Diabetes Addressing Importance Issues in Diabetes Care? Diabetologia, 56, 1226-1235.
http://dx.doi.org/10.1007/s00125-013-2890-4
[3] Fravel, M.A., McDanel, D.L., Ross, M.B., Moores, K.G. and Starry, M.J. (2011) Special Considerations for Treatment of Type 2 Diabetes Mellitus in the Elderly. American Journal of Health-System Pharmacy, 68, 500-509.
http://dx.doi.org/10.2146/ajhp080085
[4] Kirkman, M.S., Briscoe, V.J., Clark, N., et al. (2012) Diabetes in Older Adults. Diabetes Care, 35, 2650-2664.
http://dx.doi.org/10.2337/dc12-1801
[5] Sinclair, A., Morley, J.E., Rodriguez-Mañas, L., et al. (2012) Diabetes Mellitus in Older People: Position Statement on Behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older eople (EDWPOP), and the International Task Force of Experts in Diabetes. Journal of the American Medical Directors Association, 13, 497-502.
http://dx.doi.org/10.1016/j.jamda.2012.04.012
[6] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al., the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD) (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364-1379.
http://dx.doi.org/10.2337/dc12-0413
[7] Halimi, S., Raccah, D., Schweizer, A. and Dejager, S. (2010) Role of Vildagliptin in Managing Type 2 Diabetes Mellitus in the Elderly. Current Medical Research and Opinion, 26, 1647-1656.
http://dx.doi.org/10.1185/03007995.2010.485881
[8] Mathieu, C. and Bollaerts, K. (2007) Antihyperglycaemic Therapy in Elderly Patients with Type 2 Diabetes: Potential Role of Incretinmimetics and DPP-4 Inhibitors. International Journal of Clinical Practice, 154, 29-37.
http://dx.doi.org/10.1111/j.1742-1241.2007.01437.x
[9] Abbatecola, A.M., Maggi, S. and Paolisso, G. (2008) New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly: Role of Incretin Therapies. Drugs Aging, 25, 913-925.
http://dx.doi.org/10.2165/0002512-200825110-00002
[10] Maeda, H., Kubota, A., Tanaka, Y., Terauchi, Y. and Matsuba, I. (2012) The Safety, Efficacy and Predictors for HbA1c Reduction of Sitagliptin in the Treatment of Japanese Type 2 Diabetes. Diabetes Research and Clinical Practice, 95, e20-e22.
http://dx.doi.org/10.1016/j.diabres.2011.10.011
[11] Kubota, A., Maeda, H., Kanamori, A., Matoba, K., Jin, Y., Minagawa, F., Obana, M., et al. (2012) Efficacy and Safety of Sitagliptin Monotherapy and Combination Therapy in Japanese Type 2 Diabetes Patients. Journal of Diabetes Investigation, 3, 503-509.
http://dx.doi.org/10.1111/j.2040-1124.2012.00221.x
[12] Kubota, A., Matsuba, I., Saito, T., Nabe, K. and Seino, Y. (2011) Secretory Units of Islets in Transplantation Index Is a Useful Clinical Marker to Evaluate the Efficacy of Sitagliptin in Treatment of Type 2 Diabetes Mellitus. Journal of Diabetes Investigation, 2, 377-380.
http://dx.doi.org/10.1111/j.2040-1124.2011.00109.x
[13] Kubota, A., Maeda, H., Kanamori, A., Matoba, K., Jin, Y., Minagawa, F., Obana, M., et al. (2012) Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients. Journal of Clinical Medicine Research, 4, 309-313.
http://dx.doi.org/10.4021/jocmr1061w
[14] Chung, H.S. and Lee, M.K. (2011) Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal, 35, 411-417.
http://dx.doi.org/10.4093/dmj.2011.35.4.411
[15] Nonaka, K., Kakikawa, T., Sato, A., Okuyama, K., Fujimoto, G., Kato, N., Suzuki, H., et al. (2008) Efficacy and Safety of Sitagliptin Monotherapy in Japanese Patients with Type 2 Diabetes. Diabetes Research and Clinical Practice, 79, 291-298.
http://dx.doi.org/10.1016/j.diabres.2007.08.021
[16] Tajima, N., Kadowaki, T., Odawara, M., Nishii, M., Taniguchi, T. and Arjona Ferreira, J.C. (2011) Addition of Sitagliptin to Ongoing Glimepiride Therapy in Japanese Patients with Type 2 Diabetes over 52 Weeks Leads to Improved Glycemic Control. Diabetology International, 2, 32-44.
http://dx.doi.org/10.1007/s13340-011-0022-2
[17] Kashiwagi, A., Kadowaki, T., Tajima, N., Nonaka, K., Taniguchi, T., Nishii, M., Arjona Ferreira, J.C. and Amatruda, J.M. (2011) Sitagliptin Added to Treatment with Ongoing Pioglitazone for Up to 52 Weeks Improves Glycemic Control in Japanese Patients with Type 2 Diabetes. Journal of Diabetes Investigation, 2, 381-390.
http://dx.doi.org/10.1111/j.2040-1124.2011.00120.x
[18] Kadowaki, T., Tajima, N., Odawara, M., Nishii, M., Taniguchi, T. and Arjona Ferreira, J.C. (2013) Addition of Sitagliptin to Ongoing Metformin Monotherapy Improves Glycemic Control in Japanese Patients with Type 2 Diabetes over 52 Weeks. Journal of Diabetes Investigation, 42, 174-181.
http://dx.doi.org/10.1111/jdi.12001
[19] Tajima, N., Kadowaki, T., Okamoto, T., Sato, A., Okuyama, K., Minamide, T. and Arjona Ferreira, J.C. (2013) Sitagliptin Added to Voglibose Monotherapy Improves Glycemic Control in Patients with Type 2 Diabetes. Journal of Diabetes Investigation, 4, 595-604.
[20] Kadowaki, T., Tajima, N., Odawara, M., Minamide, T., Kawashima, M., Yanagida, D., Okamoto, T. and Arjona Ferreira, J.C. (2013) Efficacy and Safety of Sitagliptin Add-On Therapy in Japanese Patients with Type 2 Diabetes on Insulin Monotherapy. Diabetology International, 4, 160-172.
http://dx.doi.org/10.1007/s13340-013-0109-z
[21] Johnston, S.S., Conner, C., et al. (2012) Association between Hypoglycaemic Events and Fall-Related Fractures in Medicare-Covered Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 14, 634-643.
http://dx.doi.org/10.1111/j.1463-1326.2012.01583.x
[22] Whitmer, R.A., Karter, A.J., et al. (2009) Hypoglycemic Episodes and Risk of Dementia in Older Patients with Type 2 Diabetes Mellitus. JAMA, 301, 1565-1572.
http://dx.doi.org/10.1001/jama.2009.460
[23] Bonds, D.E., Miller, M.E., et al. (2010) The Association between Symptomatic Severe Hypoglycemia and Mortality in Type 2 Diabetes: Retrospective Epidemiological Analysis of the ACCORD Study. BMJ, 340, b4909.
http://dx.doi.org/10.1136/bmj.b4909
[24] Iwakura, T., Sasaki, S., et al. (2012) Clinical Analysis of 135 Type 2 Diabetes Patients with Severe Drug-Induced Hypoglycemia. Journal of the Japan Diabetes Society, 55, 857-865.
[25] Pratley, R.E., Rosenstock, J., et al. (2007) Management of Type 2 Diabetes in Treat-Nañve Elderly Patients: Benefits and Risks of Vildagliptin Monotherapy. Diabetes Care, 30, 3017-3022.
http://dx.doi.org/10.2337/dc07-1188
[26] Schweizer, A., Dejager, S., et al. (2011) Clinical Experience with Vidagliptin in the Management of Type 2 Diabetes in a Patient Population ≥75 Years: A Pooled Analysis from a Database of Clinical Trials. Diabetes, Obesity and Metabolism, 13, 55-64.
http://dx.doi.org/10.1111/j.1463-1326.2010.01325.x
[27] Barnett, A.H., Huisman, H., et al. (2013) Linagliptin for Patients Aged 70 Years or Older with Type 2 Diabetes Inadequately Controlled with Common Anti-Diabetes Treatments: A Randomized, Double-Blind, Placebo-Controlled Trials. The Lancet, 382, 1413-1423.
http://dx.doi.org/10.1016/S0140-6736(13)61500-7